Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance
Joydeep Ghosh, … , Rebecca J. Chan, Reuben Kapur
Joydeep Ghosh, … , Rebecca J. Chan, Reuben Kapur
Published June 13, 2016
Citation Information: J Clin Invest. 2016;126(7):2621-2625. https://doi.org/10.1172/JCI84565.
View: Text | PDF
Brief Report Hematology

S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance

  • Text
  • PDF
Abstract

Hyperactivation of the mTOR pathway impairs hematopoietic stem cell (HSC) functions and promotes leukemogenesis. mTORC1 and mTORC2 differentially control normal and leukemic stem cell functions. mTORC1 regulates p70 ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E–binding (eIF4E-binding) protein 1 (4E-BP1), and mTORC2 modulates AKT activation. Given the extensive crosstalk that occurs between mTORC1 and mTORC2 signaling pathways, we assessed the role of the mTORC1 substrate S6K1 in the regulation of both normal HSC functions and in leukemogenesis driven by the mixed lineage leukemia (MLL) fusion oncogene MLL-AF9. We demonstrated that S6K1 deficiency impairs self-renewal of murine HSCs by reducing p21 expression. Loss of S6K1 also improved survival in mice transplanted with MLL-AF9–positive leukemic stem cells by modulating AKT and 4E-BP1 phosphorylation. Taken together, these results suggest that S6K1 acts through multiple targets of the mTOR pathway to promote self-renewal and leukemia progression. Given the recent interest in S6K1 as a potential therapeutic target in cancer, our results further support targeting this molecule as a potential strategy for treatment of myeloid malignancies.

Authors

Joydeep Ghosh, Michihiro Kobayashi, Baskar Ramdas, Anindya Chatterjee, Peilin Ma, Raghuveer Singh Mali, Nadia Carlesso, Yan Liu, David R. Plas, Rebecca J. Chan, Reuben Kapur

×

Figure 3

S6K1 is a positive regulator of HSC self-renewal and prolongs the survival of leukemic mice.

Options: View larger image (or click on image) Download as PowerPoint
S6K1 is a positive regulator of HSC self-renewal and prolongs the surviv...
(A) Quantitative analysis of donor-derived chimerism in PB of secondary recipients of WT and S6k1–/– LT-HSCs; mean ± SEM. *P < 0.001, 1-way ANOVA. n = 9–10/group. (B) Quantitative analysis of donor-derived chimerism in PB of tertiary transplant recipients of WT and S6k1–/– LT-HSCs; mean ± SEM. *P < 0.001, 1-way ANOVA. n = 7–10/group. (C) Expression of Cdkn1a in CD45.2+ LSK cells isolated from WT and S6k1–/– secondary recipients depicted in part A; mean ± SD. *P < 0.001. Experiment performed in triplicate. (D) Kaplan-Meier survival curves of secondary recipients of MLL-AF9 fusion gene transduced with WT or S6k1–/– cells derived from primary recipients. *P < 0.001 (n = 17/group). (E) Quantitative representation of Ki-67–negative GFP+ Gr1–Mac1– Sca1–c-Kit+ cells in BM and spleen of secondary recipients (from part D) of WT or S6k1–/– AML cells expressing MLL-AF9; mean ± SEM. *P < 0.01, t test. n = 5 mice/group. Data representative of 2 independent experiments. (F) Phosphorylation level of AKT and 4E-BP1 in WT and S6k1–/– HSC/Ps expressing MLL-AF9; n = 2. (G) Phosphorylation level of mTOR and 4E-BP1 in MA9-3 cells following treatment with PF-4708671; n = 3. (H) Kaplan-Meier survival curves of NOD/SCID mice transplanted with MA9-3 cells treated with either vehicle or PF-4708671. *P < 0.05. n = 7/group.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts